Susana N Banerjee

33PUBLICATIONS
258CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsPredictive and prognostic markersCancer geneticsHaematological tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (33)

|Oct 27, 2026
PARP Inhibitors in the Management of Ovarian Cancer: ASCO Living Guideline, Version 2026.1.0.

|Oct 22, 2026
Carboplatin Plus Mirvetuximab Soravtansine In Platinum-Sensitive Ovarian Cancer: A Phase 2 Nonrandomized Clinical Trial.

|May 15, 2026
Trastuzumab deruxtecan in HER2-expressing gynecologic cancers from DESTINY-PanTumor02: antitumor activity, safety, and exploratory biomarker analyses.

|Apr 08, 2026
Phase Ib trial of SL-172154, a bispecific CD47 inhibitor and CD40 agonist Fc-fusion protein, in combination with mirvetuximab soravtansine or pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer.

Yvette Drew, Lucy Gilbert, Alejandro Martinez Bueno

|Mar 05, 2026
Ovarian cancer.

Clare L Scott, Susana Banerjee, Florence Joly

|Dec 11, 2025
Molecular Profiling and Tumor Biomarker Analysis of GOG281/LOGS: A Positive Late-Phase Trial of Trametinib for Recurrent/Persistent Low-Grade Serous Ovarian Carcinoma.

Robert L Hollis, Austin Miller, Heather A Lankes

Pageof 6

Frequent Collaborators

9 joint publications

Ana Oaknin

6 joint publications

David M O'Malley

6 joint publications

Kathleen Nadine Moore

5 joint publications

Rebecca S Kristeleit